Author

Tamta Korinteli

Observed name: Korinteli, Tamta

Institution: National Center for Tuberculosis and Lung Disease

Observed institution: National Center for Tuberculosis and Lung Disease

ORCID: 0000-0001-6029-1231

Observed ORCID: 0000-0001-6029-1231

OpenAlex ID: A5092274901

SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen

2023 · Lilibeth Arias, Kennedy Otwombe, et al. · Trials · 20

Adjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a phase IIA open-label pilot clinical trial

2026 · Kaori L. Fonseca, Judith Farrés, et al. · Nature Communications · 8

Acetylsalicylic Acid and Ibuprofen as Adjunctive Therapy for Tuberculosis

2025 · Lilibeth Arias, Ziyaad Waja, et al. · medRxiv · 1

Inflammatory and transcriptional profiles associated with structural and functional recovery in pre-XDR/XDR tuberculosis

2026 · Juan M García-Illarramendi, Chiara Sopegno, et al. · International Journal of Infectious Diseases

Incidence of and Risk Factors for Tuberculosis Among Patients Treated for Hepatitis C: a Population-based Cohort Study

2026 · Tamta Korinteli, Nestani Tukvadze, et al. · Open Forum Infectious Diseases

Late Breaking Abstract - Ibuprofen and acetylsalycilic acid as adjunctive to anti-tuberculosis treatment: Phase II clinical trial

2025 · Cristina Vilaplana Massaguer, Ziyaad Waja, et al. · European Respiratory Journal

Works count: 8

Citation count: 29

H-index: 2

I10-index: 1